Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2025
0mins
Source: Globenewswire
Appointment Announcement: Matinas BioPharma has appointed Evelyn D’An as an independent director and Chair of the Audit Committee, effective February 5, 2025, bringing extensive corporate governance and financial oversight experience to the board.
Company Overview: Matinas BioPharma is a biopharmaceutical company that focuses on innovative therapies utilizing its lipid nanocrystal platform technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
